About 300 children and adolescents will take part in the clinical trial to be developed in Havana.
Jun 11, 2021
On Thursday, Cuba’s Center for State Control of Medicines, Equipment, and Medical Devices (CECMED) approved the first clinical trial of the “Soberana” COVID-19 vaccine in people between 3 and 18 years old.
The Finlay Vaccine Institute (IFV) stated this trial aims to evaluate the safety, reactogenicity, and immunogenicity of experimental vaccines Soberana 02 and Soberana Plus, both of which are administered in two doses 28 days apart.
IFV Director Vicente Verez said that 350 children and adolescents will take part in the clinical trial to be developed in Havana La Habana.
He also pointed out that both products were shown to be safe when applied to adults who only had mild or moderate reactions after being vaccinated
The U.S. embargo delays the development of Cuban vaccine candidates against COVID-19.
This unjust policy delays health interventions and hampers the fight against the contagious disease.#StopTheEmbargo#ItsAVirusToo pic.twitter.com/UaAB5wtmKP
— Cuba Vs Bloqueo (@cubavsbloqueo) June 9, 2021
Verez mentioned that under-three-year-old kids will not participate in this trial because their health conditions are often complex.
His institution is preparing another clinical trial of the Soberana 1 vaccine in pediatric ages. This one will be developed in Cienfuegos province.
As of May 27, Cuba had reported 18,249 pediatric COVID-19 cases, 983 of which were in under-12-months kids.
The neoliberal governments of Latin America could learn a lot from Cuba and Bolivia's massive investments in education for everyone irrespective of ability to pay. pic.twitter.com/i7ohNSDeIB
— teleSUR English (@telesurenglish) December 17, 2017
Published at www.telesurenglish.net
